Supplemental Table 6 from Constitutive EGFR Activation Induced by PTPRR Downregulation Confers Resistance to KRAS Inhibitors
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Baseline clinical characteristics of 17 NSCLC patients treated with EGFR-TKIs and classified according to PTPRR mRNA abundance in pretreatment tumor specimens as determined by RNA-sequencing analysis.
Fields of Study & Subjects
Lung Cancer Treatments and Mutations
Protein Tyrosine Phosphatases
HER2/EGFR in Cancer Research
Publication details
- Publication date
- 2 April 2026
- Language
- EN